Omega-7 (Sea Buckthorn) — Research Profile

Omega-3 (EPA/DHA) is a polyunsaturated fatty acid that primarily works through anti-inflammatory pathways and membrane fluidity. Omega-7 (palmitoleic acid) is a monounsaturated fatty acid that functions as a lipokine — a signaling molecule between fat tissue and the liver. They have complementary but distinct mechanisms: omega-3 excels at reducing triglycerides and inflammation, while omega-7 uniquely influences hepatic lipogenesis and insulin signaling. They can be safely taken together.

For targeted cardiovascular support, purified palmitoleic acid supplements are preferred because they deliver a concentrated dose (>50% palmitoleic acid) without excess palmitic acid (a saturated fat that may counteract benefits). Sea buckthorn oil typically contains only 30-35% palmitoleic acid alongside significant palmitic acid. However, sea buckthorn oil offers additional benefits from its carotenoids and vitamin E content, making it better suited for mucosal health and skin support.

The evidence is promising but still emerging. There is one well-designed RCT (Bernstein et al., 2014) showing impressive triglyceride and CRP reductions ^[1], plus strong mechanistic data from animal studies. However, we lack large-scale human trials with cardiovascular endpoints. Omega-7 is reasonable to try for people seeking additional cardiometabolic support beyond omega-3, especially if they have elevated CRP or triglycerides, but it should not replace proven interventions like omega-3, statins, or lifestyle changes.

Pulp or whole-berry oil is the omega-7-rich form, at up to about 43% palmitoleic acid, while seed oil is very low in it (under 0.5%) and is instead richer in omega-3 and omega-6. The clinical dry-eye evidence used a whole-berry oil (SBA24) in softgels at 2 g/day, so an oil delivered as softgels is the best-supported form.

The strongest human evidence is for dry eye: 2 g/day of sea buckthorn oil for 3 months produced a significantly smaller rise in tear film osmolarity and less eye redness and burning than placebo. Cardiometabolic and skin/mucous-membrane benefits have been suggested in smaller studies but are not well established. A purified-palmitoleic-acid trial on C-reactive protein and lipids that this page previously cited (PMID 34144766) has been formally retracted and should not be treated as evidence.

Human trials have used roughly 2 to 3 g of sea buckthorn oil daily; the dry-eye study used 2 g/day for 3 months. No standardized or official dose has been set, and authorities note there is not enough reliable information to define an optimal intake, so the trial range is the most that can be said.

Time of day has not been directly compared in trials, so no evidence shows one time works better than another. Since it is a fat-based oil, taking it with a meal is a reasonable way to aid absorption; the dry-eye trial simply had participants take 2 g daily without specifying a time.

Documented side effects are uncommon and mostly tied to specific uses: a case report describes generalized skin yellowing from the oil's carotenoids at high intake, and topical application can cause red or itchy skin in some people. Oral tolerability has not been well characterized in published trial data, and as with any oil, mild digestive upset is possible.

Sea buckthorn may slow blood clotting, so combining it with anticoagulant or antiplatelet drugs such as warfarin, aspirin, or clopidogrel could increase bruising and bleeding risk. It may also lower blood pressure, potentially adding to the effect of blood-pressure medications, and it should be stopped at least 2 weeks before surgery.

People with dry-eye symptoms have the clearest rationale, since that is where 2 g/day for 3 months showed measurable benefit, and it may also appeal to those specifically seeking a dietary source of omega-7 (palmitoleic acid). It is best avoided by anyone on blood thinners or blood-pressure medication, those approaching surgery, and, for lack of safety data, during pregnancy or breastfeeding.

In the only oral human trial in dry-eye sufferers, benefits (a smaller rise in tear film osmolarity and less eye redness and burning) were measured after 2 g of sea buckthorn oil daily for 3 months; earlier time points were not reported, so a faster timeline within those months is not established. Because omega-7 acts by gradually shifting membrane and lipid composition rather than through acute pharmacology, studied outcomes are assessed over weeks to months, not days.

Oral sea buckthorn oil is rated possibly safe for use up to about 90 days; safety beyond roughly 3 months has not been established in controlled studies. The longest clinical trial ran only 3 months at 2 g/day, and no data support indefinite daily use, so extended daily intake is not backed by evidence.

No tolerable upper intake level exists for omega-7 or sea buckthorn oil, and it is not an essential nutrient with a defined requirement, so there is no established safe ceiling. Very high intake has been linked in a case report to generalized yellowing of the skin from the oil's carotenoids, which reverses on stopping, and because the oil can slow blood clotting, larger amounts raise a theoretical bleeding concern.

No supplement pairings have been formally tested with sea buckthorn omega-7, so no specific combination is evidence-based, and consumer monographs list no herb-or-supplement interactions for it. The one documented mechanism worth noting is that the oil may slow blood clotting; on that basis alone, taking it alongside other products that can also affect clotting is a theoretical bleeding caution rather than a demonstrated interaction.

The omega-7 (palmitoleic acid) content depends heavily on which part of the berry the oil comes from: pulp and peel oil can reach up to 43% palmitoleic acid, whereas seed oil contains under 0.5%. Choose a product that specifies pulp or whole-berry oil and lists its palmitoleic acid percentage; whole-berry oils like the SBA24 preparation used in the dry-eye trial are the type with actual human data.